Rejoyn isn't a wellness app.

It's a 6-week prescription brain-training program that is designed to help improve how the brain processes emotions.

In a clinical trial, adding Rejoyn to an antidepressant resulted in:

  • Three arrows pointing down to indicate the reduction in depression symptoms

    Reduced symptoms of depression

  • A zero with a line through the center to indicate zero side effects from Rejoyn

    Zero side effects from Rejoyn

Find out more in the press release for Rejoyn

Rejoyn will be available in summer 2024 for download on the App Store® or Google Play™.

App Store is a service mark of Apple Inc., registered in the United States and other countries.
Google Play and the Google Play logo are trademarks of Google LLC.

INDICATION: Rejoyn is a prescription digital therapeutic for the treatment of Major Depressive Disorder (MDD) symptoms as an adjunct to clinician-managed outpatient care for adult patients with MDD age 22 years and older who are on antidepressant medication. It is intended to reduce MDD symptoms.

SAFETY INFORMATION: Rejoyn is not intended to be used as a standalone treatment. Rejoyn does not replace your current medication, including medication for treatment of MDD. You should continue your current treatment as directed by your healthcare provider.

Rejoyn cannot send alerts or warnings to your healthcare provider. If you feel that your depression symptoms are worsening or if you have feelings or thoughts of harming yourself or others, please contact your healthcare provider, dial 911, or go to the nearest emergency room immediately.